Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up virology markers after EYP001-103 Part B
NL-OMON48213Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonafexor and pegylated interferon alpha in Chronic Hepatitis B (CHB), sponsored by Amsterdam University Medical Center. Primary endpoints: Quantitative HBV DNA, Quantitative HBsAg and 2 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
vonafexorpegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON48213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48213.